Revance sees Q4 collection revenue at $34M-$35M

Yesterday morning, Revance announced that it "expects preliminary unaudited fourth quarter Collection revenue to be between $34.0 million and $35.0 million, representing an approximately 45% increase from the same period last year, and full year 2022 preliminary unaudited RHA Collection revenue of between $106.5 million and $107.5 million, representing an approximately 50% increase from full year 2021." CEO Mark Foley stated: "We are very pleased to end 2022 on a strong note, highlighted by continued growth and adoption of the RHA(R) Collection along with an excellent start to our early experience program for DAXXIFY. In particular, we are very encouraged to see the early traction of our DAXXIFY(R) PrevU program, which was initiated in Q4 and further benefited from the impact of traditional seasonality. We have been very pleased with the initial response to, and the positive feedback on, the product’s performance and ease of practice integration. While we are still in the beginning phase of the PrevU program, our progress thus far gives us confidence in our commercial strategy and in DAXXIFY’s full-scale commercial launch, which is expected to begin in late Q1/early Q2 of 2023. Looking ahead, our strategic priorities in the new year will center on delivering a successful commercial launch for DAXXIFY(R), continuing the growth of our aesthetics portfolio, and unlocking our therapeutics opportunity by obtaining the FDA’s approval of DAXXIFY(R) for cervical dystonia."